Memphasys believes it has found a quicker, cheaper way to get its Felix sperm separation system cleared by US regulators. It could open a door to an IVF market worth about US$5.9 billion.
Paradigm Biopharmaceuticals has suffered a setback after an independent monitoring board found that its Phase 3 knee ...
Melbourne kidney disease drug developer Dimerix has drawn $17 million from a $34 million loan facility as its lead candidate ...
The final visit took place in the United States this week. The company told investors that topline results from the XanaMIA ...
Perth company Patrys has started in-human testing of its intravenous version of the antipsychotic quetiapine. The first ...
Prescient Therapeutics has raised $6 million from shareholders and investors. The money will fund its lead cancer drug ...
BCAL Diagnostics has started a phased rollout of Avantect Multi-Cancer in Sydney and Melbourne and plans to expand nationally ...
The Australian nuclear medicine company has agreed to lead a merger with ITM Isotope Technologies Munich SE, paying US$1.65 ...
A Melbourne biotechnology company betting on immune cell cargo as a treatment for Alzheimer's disease has enlisted one of ...
Anthropic has expanded its AI for Science commitment in Australia with an additional $10 million in Claude API credit grants, ...
Genetic Signatures and Microba Life Sciences have agreed on the principal commercial terms of a merger that would combine two ...
Sydney-based company Nyrada has raised $12.0 million in new equity capital before costs, with its own board committing $5.125 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results